PharmEng International Inc. TSX VENTURE: PII

TORONTO, ONTARIO--(Marketwire - Nov. 7, 2008) - PharmEng International Inc. (TSX VENTURE:PII), a full-service consulting and contract manufacturing company, today announced the resignation of George Unsworth from the Board of Directors. As a former partner of Deloitte & Touche LLP, George's resignation is the result of a conflict with the auditor's internal independence policy. The Company's current auditors are Deloitte & Touche LLP. George became a Board member June 22, 2006 and served as the Chair of the Audit Committee.

Stock Option Grants

At a Board meeting October 3, 2008, the Board approved and granted 1,000,000 options of the Company stock to a senior executive with a grant date of October 7, 2008. Under the Company Stock Option Plan, the options were granted at a strike price of $0.30, being the closing market price at the granting date, with a term of 4 years and will vest in equal amounts during the next 12, 24 and 36 months from the granting date.

About PharmEng International Inc. PharmEng International Inc., headquartered in Toronto, Canada, is a full-service consulting and contract manufacturing company that serves the pharmaceutical and biotechnology industries in North America and internationally. Consulting services include project management, engineering, GMP, validation, calibration, regulatory compliance and certified training. Contract manufacturing includes pharmaceutical support, formulation development, laboratory testing, and finished solid dosage and liquid products.

PharmEng's shares trade on the TSX Venture Exchange under the symbol PII. To find out more about PharmEng International Inc. (TSX-V: PII), visit our website at www.pharmeng.com.

FORWARD LOOKING STATEMENTS

Certain statements in this press release may include "forward-looking" statements which involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of PharmEng to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. When used in this press release, such statements use such words as "may", "will", "expect", "anticipate", "project", "believe", "plan", and other similar terminology. The risks and uncertainties are detailed from time to time in reports filed by PharmEng with the securities regulatory authorities in all of the provinces and territories of Canada. New risk factors may arise from time to time and it is not possible for management to predict all of those risk factors or the extent to which any factor or combination of factors may cause actual results, performance and achievements of PharmEng to be materially different from those contained in forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.